CD274 and renal cell carcinoma: A retrospective analysis evaluated antitumor activity and safety of 45 patients with metastatic RCC who had prior exposure to anti-PD1 or anti-PDL1 antibodies and were subsequently treated with salvage Ipilimumab and Nivolumab.